6 October 2014Big Pharma

Teva gets under Leo’s skin, knocks out two patents

Drug business Teva invalidated two patents held by Leo Pharma today (October 6) and will seek to launch a generic version of one of the company’s skin condition treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Teva gets under Leo’s skin, knocks out two patents

More on this story

Editor's picks

Editor's picks

More features